The firm, which specialises in commercialising public and corporate research, has closed its largest fund to date.
Arch Venture Partners, a US-based venture capital firm with a focus on commercialising university research, closed its eleventh fund at $1.85bn yesterday to back biotechnology companies.
Fund XI will seek both to create and invest in early-stage companies across areas including infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging medicines, genomic and biological tools and data sciences.
The fund will also seek out new approaches around diagnostics and therapies. It is the firm’s largest vehicle…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
